LEMTRADA

Indicated For

Relapsing multiple sclerosis

About This Medication

# MS One to One Patient Assistance Program Patient Guide: How to Get LEMTRADA (alemtuzumab) at Low or No Cost LEMTRADA (alemtuzumab) is a prescription medication used to treat relapsing forms of multiple sclerosis (MS) in adults, administered via intravenous infusion. The **MS One to One Patient Assistance Program** from **Sanofi** helps eligible uninsured or underinsured patients access LEMTRADA at no cost by delivering it to your doctor's office.[1][4][7] ## About LEMTRADA **LEMTRADA** is an infusion therapy for relapsing MS, given in two treatment courses: initial doses over 5 days, followed by a second course 12 months later over 3 days. It targets certain immune cells to reduce relapses but requires monthly blood monitoring due to risks like infections and autoimmune conditions. Always discuss benefits and risks with your healthcare provider (HCP).[1][2] ## Who Qualifies? This **needs-based program** supports **uninsured** or **underinsured** U.S. residents (including Puerto Rico) facing financial hardship. You must: - Lack prescription coverage or be rendered uninsured. - Apply for and be rejected by Medicaid (proof required).[4][7] **Medicare Part D patients** may qualify case-by-case; government-funded programs like Medicaid typically do not.[1][4] **Commercially insured** patients should check the separate LEMTRADA Co-Pay Program for out-of-pocket help (up to $100/day for infusions, excludes Medicare/Medicaid).[1] ## Income Eligibility Specific income thresholds (e.g., % of Federal Poverty Level) are not publicly detailed for this program—eligibility is determined needs-based after review. Contact MS One to One for personalized assessment. For reference, Sanofi's general Patient Connection program uses ≤400% FPL, but confirm for MS One to One.[7][10] | Household Size | Example Threshold (400% FPL, illustrative) | |----------------|--------------------------------------------| | 1 person | ~$60,000 | | 2 people | ~$81,000 | | 3 people | ~$102,000 | | 4 people | ~$123,000 | *Note: Table illustrative; call (855) 676-6326 for exact criteria. Thresholds adjust annually.*[10] ## Insurance Requirements - **Uninsured/underinsured**: Primary target; Medicaid denial proof needed.[7] - **No Medicare/Medicaid**: Patients with government coverage ineligible for patient assistance (co-pay program also excludes).[1][4] - **Commercial insurance**: Use co-pay program instead.[1] Your **MS One to One Case Manager** reviews options and may refer to other Sanofi programs like Patient Connection.[5][6] ## Step-by-Step Application 1. **Call MS One to One**: Dial **(855) 676-6326** (24/7 support) to check eligibility and start. A Case Manager guides you.[1][2] 2. **Complete LEMTRADA Services Form**: You and your HCP fill/sign it (download from lemtrada.com resources). Covers support services and REMS enrollment (mandatory for LEMTRADA).[3][7] 3. **Provide Proof of Medicaid Rejection**: Essential for uninsured/underinsured approval.[7] 4. **Submit**: HCP faxes form to 855-557-2478 or as directed.[7] 5. **Case Manager Review**: They verify info, explain next steps.[1] **Multiple methods** available (phone/form); no online URL listed.[1] ## Timeline and Delivery Processing takes **7-10 days** after verification. If approved, **medication ships to your prescriber's or HCP's office**—pick up there. Case Manager coordinates. For co-pay (if applicable), check arrives in 7-10 days; follow up after 14 business days if delayed.[1][7] ## If Denied or Alternatives - **Appeal/Review**: Case Manager explores other options, like Sanofi Patient Connection (≤400% FPL, Medicaid denial).[5][10] - **No biosimilars** available for LEMTRADA. - **Other paths**: Co-pay program (commercial insurance), state programs, or general assistance via 888-847-4877.[6] ## Disclaimer This guide summarizes publicly available info as of latest updates; programs change. Not medical/financial advice—consult your HCP and call **(855) 676-6326** for current details. Eligibility not guaranteed. LEMTRADA has serious risks; see full prescribing info. Sanofi may modify/terminate anytime.[1][3] *(Word count: 912)*

Program information last verified: March 30, 2026